UCB SA (EBR:UCB)
203.50
+1.70 (0.84%)
Oct 9, 2026, 5:35 PM CET
UCB SA Employees
UCB SA had 9,000 employees as of June 30, 2026. The number of employees decreased by 765 or -7.83% since the number was reported on December 31, 2025. That makes UCB SA the 3,641st largest employer in the world and 14th in Belgium.
Employees
9,000
Change
-765
Growth
-7.83%
Revenue / Employee
€947,111
Profits / Employee
€243,778
Market Cap
38.80B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 9,000 | -765 | -7.83% | 9,000 | 0 |
| Dec 31, 2025 | 9,765 | 713 | 7.88% | 9,765 | 0 |
| Dec 31, 2024 | 9,052 | -31 | -0.34% | 9,052 | 0 |
| Dec 31, 2023 | 9,083 | 380 | 4.37% | 8,450 | 633 |
| Dec 31, 2022 | 8,703 | 142 | 1.66% | 8,108 | 595 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| argenx SE | 1,863 |
| Onward Medical | 137 |
| European Medical Solutions | 119 |
| Hyloris Pharmaceuticals | 54 |
| Oxurion NV | 26 |
| BioSenic | 7 |
| Celyad Oncology | 5 |
UCB SA News
- 1 day ago - UCB Dedicates Site for New U.S. Biologics Manufacturing Campus in Georgia - PRNewsWire
- 9 days ago - UCB SA Transcript: Investor update - Transcripts
- 9 days ago - UCB SA Slides: Investor update - Filings
- 17 days ago - UCB SA Transcript: J.P. Morgan European Healthcare CEO Call Series - Transcripts
- 17 days ago - UCB SA Transcript: Bank of America Global Healthcare Conference - Transcripts
- 2 months ago - UCB upgraded to Hold from Underperform at Jefferies - TheFly
- 2 months ago - UCB SA Earnings Call Transcript: H1 2026 - Transcripts
- 2 months ago - UCB SA Earnings release: H1 2026 - Filings